Immunic (IMUX) Cash from Financing Activities (2013 - 2026)

Immunic has reported Cash from Financing Activities for 14 years, with the latest figure at $188.6 million in Q1 2026.

• Quarterly Cash from Financing Activities changed N/A year-over-year to $188.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $254.2 million (up 330054.55% YoY) and the FY2025 annual result came in at $65.6 million, down 12.03% from the prior year.
• Cash from Financing Activities climbed to $188.6 million in Q1 2026 per IMUX's latest filing, from $59000.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $188.6 million in Q1 2026 and troughed at $51000.0 in Q1 2023.
• A 5-year average of $35.5 million and a median of $5.3 million in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities plunged 99.83% in 2023, then jumped 145907.84% in 2024.
• Over 5 years, Cash from Financing Activities stood at $56.0 million in 2022, then slumped by 98.92% to $604000.0 in 2023, then plunged by 87.25% to $77000.0 in 2024, then retreated by 23.38% to $59000.0 in 2025, then surged by 319632.2% to $188.6 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $188.6 million, $59000.0, and $65.5 million for Q1 2026, Q4 2025, and Q2 2025 respectively.